Patent · US Revoked

IL-6 antibodies

US10947309B2 · kind B2 · utility

0Cited by
36References
23Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 6, 2015
Grant dateMar 16, 2021
Priority date
Expiry dateSep 25, 2037

Classification

  • Technology area (CPC —)General

Abstract

Improved IL-6 antibodies are provided. Uses of the antibodies in the treatment of IL-6-related diseases, e.g., ocular diseases such as diabetic macular edema, are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.